Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Spero Therapeutics reported a Q2 net loss of $9.6 million, or $0.16 per share, with no revenue recognized compared to $14.2 million in the prior year, but highlighted significant operational progress during the quarter. The company closed a $105 million non-dilutive royalty financing backed by Utebzi milestones and entered an exclusive license agreement with Innovent Biologics for SP001, extending its cash runway into the second half of 2029. Management also recapped the June FDA approval of Utebzi and announced the appointment of Dr.
Key figures
- Revenue
- 0
- Guidance
- Cash runway sufficient to fund operating expenses and capital expenditure into the second half of 2029
- Deal Value Usd
- 105000000
- Net loss
- 9600000
- Rd expenses
- 3400000
- Gna expenses
- 6500000
- Cash and equivalents
- 50800000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.